Summary
Cannot be reliably audited because the prompt provides only limited FDA label excerpts (mechanism description, limitations of use, myelosuppression/neuropathy warnings, and an MAOI interaction statement) rather than full sections for indications, contraindications, dosage, boxed warnings, adverse reactions, and other items. Several claims in the AI list are not supported or are not verifiable from the supplied excerpts (e.g., indications/organisms like MRSA/VRE, patent/generic-market statements, and cost/marketing history).
Category Scores
Accurate Statements
Linezolid is an oxazolidinone-class antibacterial agent (label excerpt: 'synthetic antibacterial agent of the oxazolidinone class').
11 DESCRIPTION: 'contains linezolid, which is a synthetic antibacterial agent of the oxazolidinone class.'
Linezolid should not be used in patients taking monoamine oxidase inhibitors (MAOIs) or within two weeks of taking such products.
7 DRUG INTERACTIONS 4.2 Monoamine Oxidase Inhibitors: 'Linezolid should not be used ... which inhibits monoamine oxidases A or B ... or within two weeks of taking any such medicinal product.'
Myelosuppression (including anemia, leukopenia, pancytopenia, thrombocytopenia) has been reported; complete blood counts should be monitored weekly in specified patients and discontinuation should be considered with worsening myelosuppression.
5.1 Myelosuppression: 'Myelosuppression ... has been reported...' and 'Complete blood counts should be monitored weekly...' and 'Discontinuation ... should be considered...'
Peripheral and optic neuropathies have been reported, primarily with longer than the maximum recommended duration of 28 days; visual function should be monitored in patients taking ZYVOX for extended periods (≥ 3 months) and in those with new visual symptoms.
5.2 Peripheral and Optic Neuropathy: mentions >28 days association and 'Visual function should be monitored ... (≥ 3 months) and ... new visual symptoms...'
Unsupported Statements
Linezolid works by inhibiting bacterial protein synthesis.
No mechanism-of-action detail is provided in the supplied excerpts beyond 'ZYVOX is an antibacterial drug' and a link placeholder to Microbiology (12.4); the specific claim of protein-synthesis inhibition is not stated.
Linezolid has a mechanism distinct from other antibiotic classes.
Not stated in the supplied excerpts.
Linezolid is effective against certain multidrug-resistant Gram-positive bacteria, including MRSA.
No indication/microbiology spectrum supporting MRSA is present in the provided excerpts.
Linezolid is effective against certain multidrug-resistant Gram-positive bacteria, including VRE.
No indication/microbiology spectrum supporting VRE is present in the provided excerpts.
The original patents for linezolid have expired.
No patent/legal history information is provided in the supplied excerpts.
Linezolid may still benefit from various forms of market exclusivity (e.g., new patents or regulatory exclusivities).
No exclusivity/legal information is provided in the supplied excerpts.
Once patent exclusivity expires ... generic versions ... can be developed.
Not stated in the supplied excerpts.
Generic approval ... involves demonstrating bioequivalence.
No regulatory approval process information is provided in the supplied excerpts.
Generic approval ... involves meeting strict regulatory standards.
Not stated in the supplied excerpts.
For certain infections, alternative antibiotics may be available depending on the specific pathogen and its susceptibility profile.
Not stated in the supplied excerpts.
Linezolid remains a critical option for specific multidrug-resistant Gram-positive infections where other treatments are ineffective or contraindicated.
No such indication/wording is included in the provided excerpts.
Linezolid is generally considered a high-cost antibiotic... cost varies by formulation/dosage/duration/geographic location.
No cost/economic statements are present in the supplied excerpts.
The original developer of linezolid was Pharmacia; Pharmacia was acquired by Pfizer; Pfizer markets linezolid under the brand name Zyvox.
No company/history/marketing statements are present in the supplied excerpts.
As patents expire, other pharmaceutical companies may manufacture and market generic versions of linezolid.
Not stated in the supplied excerpts.
Linezolid is associated with potential side effects.
General statement not explicitly supported by supplied excerpts; label excerpt does not directly state this phrasing.
Linezolid can cause peripheral neuropathy.
Partially related to the label (peripheral neuropathy is mentioned), but the AI claim is broad and lacks the label-specified context; however 'peripheral ... neuropathies have been reported' is supported. The issue is that other elements in this category are handled under 'warnings'. (If treated strictly, this exact phrasing is still supported as a component of the warning; therefore it is not counted as unsupported here.)
Linezolid can cause optic neuropathy.
Supported as part of 'Peripheral and optic neuropathies have been reported'.
Linezolid has a mechanism distinct from other antibiotic classes.
Not stated in the supplied excerpts.
Linezolid is prescribed for serious infections caused by susceptible Gram-positive bacteria.
No indication wording is provided in the supplied excerpts.
Linezolid is used to treat community-acquired pneumonia.
Not stated in the supplied excerpts.
Linezolid is used to treat hospital-acquired pneumonia.
Not stated in the supplied excerpts.
Linezolid is used to treat complicated skin and skin-structure infections.
Not stated in the supplied excerpts.
Linezolid is used to treat vancomycin-resistant Enterococcus infections.
Not stated in the supplied excerpts.
The use of linezolid is typically reserved for situations where other treatment options are not suitable.
Not stated in the supplied excerpts.
Linezolid may be expensive due to costs associated with its research, development, and manufacturing.
No cost rationale is provided in the supplied excerpts.
Linezolid pricing may be influenced by market exclusivity; Linezolid pricing may be influenced by pricing strategies.
No pricing/exclusivity/strategy statements are provided in the supplied excerpts.
Contradictions
Important Omissions
Approved indication(s) as stated in the FDA-approved label (the supplied excerpts do not include the 'Indications and Usage' list itself).
Importance:
Moderate
Dosage and administration instructions (including dosing regimens and duration limits) from the label.
Importance:
Moderate
Contraindications section and boxed warnings (not provided in the supplied excerpts).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only safety-relevant label content provided supports myelosuppression monitoring and neuropathy warnings, and an MAOI interaction restriction. However, many other AI claims about indications and other factors are not verifiable from the supplied label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Not Aligned
Primary Issue
Many claims (especially indications, organism coverage like MRSA/VRE, and all patent/market/cost/company history statements) are not supported by the provided FDA label excerpts; dosage/indication sections are missing from the provided input, preventing verification.
Suggested Improvement
Limit claims to information explicitly present in the provided label excerpts (e.g., oxazolidinone class, MAOI interaction restriction, myelosuppression monitoring, and peripheral/optic neuropathy warning context) and provide the exact label text sections for Indications and Usage, Dosage/Administration, and Contraindications/Boxed Warnings if additional claims are to be audited.